These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 31667659)

  • 1. Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1).
    van der Noll R; Jager A; Ang JE; Marchetti S; Mergui-Roelvink MWJ; Lolkema MP; de Jonge MJA; van der Biessen DA; Brunetto AT; Arkenau HT; Tchakov I; Beijnen JH; de Bono JS; Schellens JHM
    Invest New Drugs; 2020 Aug; 38(4):1117-1128. PubMed ID: 31667659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2).
    van der Noll R; Jager A; Ang JE; Marchetti S; Mergui-Roelvink MWJ; de Bono JS; Lolkema MP; de Jonge MJA; van der Biessen DA; Brunetto AT; Arkenau HT; Tchakov I; Beijnen JH; De Grève J; Schellens JHM
    Invest New Drugs; 2020 Aug; 38(4):1096-1107. PubMed ID: 31637669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours.
    Yuan P; Shentu J; Xu J; Burke W; Hsu K; Learoyd M; Zhu M; Xu B
    Cancer Chemother Pharmacol; 2019 May; 83(5):963-974. PubMed ID: 30887180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study.
    Samol J; Ranson M; Scott E; Macpherson E; Carmichael J; Thomas A; Cassidy J
    Invest New Drugs; 2012 Aug; 30(4):1493-500. PubMed ID: 21590367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancer.
    Geenen JJJ; Dackus GMHE; Schouten PC; Pluim D; Marchetti S; Sonke GS; Jóźwiak K; Huitema ADR; Beijnen JH; Schellens JHM; Linn SC
    Int J Cancer; 2021 Jun; 148(12):3041-3050. PubMed ID: 33539540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
    Schouten PC; Dackus GM; Marchetti S; van Tinteren H; Sonke GS; Schellens JH; Linn SC
    Trials; 2016 Jun; 17(1):293. PubMed ID: 27323902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer.
    Lee JM; Peer CJ; Yu M; Amable L; Gordon N; Annunziata CM; Houston N; Goey AK; Sissung TM; Parker B; Minasian L; Chiou VL; Murphy RF; Widemann BC; Figg WD; Kohn EC
    Clin Cancer Res; 2017 Mar; 23(6):1397-1406. PubMed ID: 27663600
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors.
    Balmaña J; Tung NM; Isakoff SJ; Graña B; Ryan PD; Saura C; Lowe ES; Frewer P; Winer E; Baselga J; Garber JE
    Ann Oncol; 2014 Aug; 25(8):1656-63. PubMed ID: 24827126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.
    Chon HS; Kang S; Lee JK; Apte SM; Shahzad MM; Williams-Elson I; Wenham RM
    BMC Cancer; 2017 Jun; 17(1):407. PubMed ID: 28595616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187.
    Chen EX; Jonker DJ; Siu LL; McKeever K; Keller D; Wells J; Hagerman L; Seymour L
    Invest New Drugs; 2016 Aug; 34(4):450-7. PubMed ID: 27075016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer.
    Cadoo KA; Grisham RN; O'Cearbhaill RE; Boucicaut NN; Henson M; Iasonos A; Zhou Q; Sarasohn DM; Gallagher J; Kravetz S; Zamarin D; Makker V; Sabbatini PJ; Tew WP; Aghajanian C; Konner JA
    Gynecol Oncol; 2020 Apr; 157(1):214-221. PubMed ID: 31959492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results.
    Heath EI; Blumenschein GR; Cohen RB; Lorusso PM; Loconte NK; Kim ST; Ruiz-Garcia A; Chao RC; Wilding G
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):703-12. PubMed ID: 21140147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC).
    Mizugaki H; Yamamoto N; Nokihara H; Fujiwara Y; Horinouchi H; Kanda S; Kitazono S; Yagishita S; Xiong H; Qian J; Hashiba H; Shepherd SP; Giranda V; Tamura T
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1063-72. PubMed ID: 26433581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Bang YJ; Xu RH; Chin K; Lee KW; Park SH; Rha SY; Shen L; Qin S; Xu N; Im SA; Locker G; Rowe P; Shi X; Hodgson D; Liu YZ; Boku N
    Lancet Oncol; 2017 Dec; 18(12):1637-1651. PubMed ID: 29103871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.
    Lee JM; Hays JL; Annunziata CM; Noonan AM; Minasian L; Zujewski JA; Yu M; Gordon N; Ji J; Sissung TM; Figg WD; Azad N; Wood BJ; Doroshow J; Kohn EC
    J Natl Cancer Inst; 2014 Jun; 106(6):dju089. PubMed ID: 24842883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors.
    O'Brien MER; Sarker D; Bhosle J; Thillai K; Yap TA; Uttenreuther-Fischer M; Pemberton K; Jin X; Wiebe S; de Bono J; Spicer J
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):757-766. PubMed ID: 30088048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours.
    Dean E; Middleton MR; Pwint T; Swaisland H; Carmichael J; Goodege-Kunwar P; Ranson M
    Br J Cancer; 2012 Jan; 106(3):468-74. PubMed ID: 22223088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer.
    Dent RA; Lindeman GJ; Clemons M; Wildiers H; Chan A; McCarthy NJ; Singer CF; Lowe ES; Watkins CL; Carmichael J
    Breast Cancer Res; 2013; 15(5):R88. PubMed ID: 24063698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study.
    Briasoulis E; Golfinopoulos V; Karina M; Papakostas P; Pavlidis N; Fountzilas G
    Anticancer Drugs; 2010 Sep; 21(8):785-9. PubMed ID: 20647930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.